These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27806057)

  • 1. Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
    Bachelet D; Hässler S; Mbogning C; Link J; Ryner M; Ramanujam R; Auer M; Hyldgaard Jensen PE; Koch-Henriksen N; Warnke C; Ingenhoven K; Buck D; Grummel V; Lawton A; Donnellan N; Hincelin-Mery A; Sikkema D; Pallardy M; Kieseier B; Hemmer B; Hartung HP; Soelberg Sorensen P; Deisenhammer F; Dönnes P; Davidson J; Fogdell-Hahn A; Broët P;
    PLoS One; 2016; 11(11):e0162752. PubMed ID: 27806057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
    Link J; Ramanujam R; Auer M; Ryner M; Hässler S; Bachelet D; Mbogning C; Warnke C; Buck D; Hyldgaard Jensen PE; Sievers C; Ingenhoven K; Fissolo N; Lindberg R; Grummel V; Donnellan N; Comabella M; Montalban X; Kieseier B; Soelberg Sørensen P; Hartung HP; Derfuss T; Lawton A; Sikkema D; Pallardy M; Hemmer B; Deisenhammer F; Broët P; Dönnes P; Davidson J; Fogdell-Hahn A;
    PLoS One; 2017; 12(2):e0170395. PubMed ID: 28170401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ.
    Waddington KE; Papadaki A; Coelewij L; Adriani M; Nytrova P; Kubala Havrdova E; Fogdell-Hahn A; Farrell R; Dönnes P; Pineda-Torra I; Jury EC
    Front Immunol; 2020; 11():1527. PubMed ID: 32765529
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.
    Andlauer TFM; Link J; Martin D; Ryner M; Hermanrud C; Grummel V; Auer M; Hegen H; Aly L; Gasperi C; Knier B; Müller-Myhsok B; Jensen PEH; Sellebjerg F; Kockum I; Olsson T; Pallardy M; Spindeldreher S; Deisenhammer F; Fogdell-Hahn A; Hemmer B;
    BMC Med; 2020 Nov; 18(1):298. PubMed ID: 33143745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
    Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS
    Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement.
    Sethu S; Govindappa K; Quinn P; Wadhwa M; Stebbings R; Boggild M; Naisbitt D; Kimber I; Pirmohamed M; Park K; Sathish J
    Clin Immunol; 2013 Aug; 148(2):177-85. PubMed ID: 23770627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
    Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
    Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
    Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV
    Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.
    Ross C; Clemmesen KM; Svenson M; Sørensen PS; Koch-Henriksen N; Skovgaard GL; Bendtzen K
    Ann Neurol; 2000 Nov; 48(5):706-12. PubMed ID: 11079533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of natalizumab anti-drug antibodies persistency.
    Deisenhammer F; Jank M; Lauren A; Sjödin A; Ryner M; Fogdell-Hahn A; Sievers C; Lindberg R; Jensen PE; Sellebjerg F; Christodoulou L; Birchler M; Pallardy M; Auer M; Liblau R;
    Mult Scler; 2019 Mar; 25(3):392-398. PubMed ID: 29336205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of interferon beta: differences among products.
    Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
    J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.
    Deisenhammer F
    CNS Drugs; 2009; 23(5):379-96. PubMed ID: 19453200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
    Link J; Lundkvist Ryner M; Fink K; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
    PLoS One; 2014; 9(3):e90479. PubMed ID: 24608124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
    Pachner AR; Warth JD; Pace A; Goelz S;
    Neurology; 2009 Nov; 73(18):1493-500. PubMed ID: 19884577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
    Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
    Hässler S; Bachelet D; Duhaze J; Szely N; Gleizes A; Hacein-Bey Abina S; Aktas O; Auer M; Avouac J; Birchler M; Bouhnik Y; Brocq O; Buck-Martin D; Cadiot G; Carbonnel F; Chowers Y; Comabella M; Derfuss T; De Vries N; Donnellan N; Doukani A; Guger M; Hartung HP; Kubala Havrdova E; Hemmer B; Huizinga T; Ingenhoven K; Hyldgaard-Jensen PE; Jury EC; Khalil M; Kieseier B; Laurén A; Lindberg R; Loercher A; Maggi E; Manson J; Mauri C; Mohand Oumoussa B; Montalban X; Nachury M; Nytrova P; Richez C; Ryner M; Sellebjerg F; Sievers C; Sikkema D; Soubrier M; Tourdot S; Trang C; Vultaggio A; Warnke C; Spindeldreher S; Dönnes P; Hickling TP; Hincelin Mery A; Allez M; Deisenhammer F; Fogdell-Hahn A; Mariette X; Pallardy M; Broët P;
    PLoS Med; 2020 Oct; 17(10):e1003348. PubMed ID: 33125391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smokers run increased risk of developing anti-natalizumab antibodies.
    Hedström AK; Alfredsson L; Lundkvist Ryner M; Fogdell-Hahn A; Hillert J; Olsson T
    Mult Scler; 2014 Jul; 20(8):1081-5. PubMed ID: 24311118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.